Amgen and Allergan’s Mvasi (bevacizumab, biosimilar) + Combination Therapy Receives EU’s MAA Approval for Treatment of Certain Types of Cancer
Amgen’s Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China
Shots:
- The approval is based on P-III study results assessing Mvasi vs bevacizumab in patients with non-squamous NSCLC
- The study demonstrated in biosimilarity of Mvasi with bevacizumab in terms of efficacy, safety and immunogenicity
- Mvasi (bevacizumab, biosimilar) is a IgG1 mAb, binds to VEGF and inhibits the interaction of VEGF with its receptors, VEGF receptor-1 & VEGF receptor-2
Click here read full press release/ article | Ref: Amgen| Image: Thailand Medical News